{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:14:45Z","timestamp":1793196885039,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neurot.2025.e00724","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:36:39Z","timestamp":1758069399000},"page":"e00724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from na\u00efve and switch patients"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1607-543X","authenticated-orcid":false,"given":"Clara G.","family":"Chisari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lo Fermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Iacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ruscica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Realmuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Bucello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Salemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Maria","family":"Edoardo Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurot.2025.e00724_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00724_bib2","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00724_bib3","doi-asserted-by":"crossref","first-page":"1101379","DOI":"10.3389\/fncel.2023.1101379","article-title":"The interplay between T helper cells and brain barriers in the pathogenesis of multiple sclerosis","volume":"17","author":"Angelini","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00724_bib4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00724_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13041-024-01077-7","article-title":"The brain cytokine orchestra in multiple sclerosis: from neuroinflammation to synaptopathology","volume":"17","author":"Amoriello","year":"2024","journal-title":"Mol Brain"},{"key":"10.1016\/j.neurot.2025.e00724_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-cellbio-100617-062518","article-title":"Non-antibody-secreting functions of B cells and their contribution to autoimmune disease","volume":"35","author":"Getahun","year":"2019","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00724_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/imm.13198","article-title":"The role of B cells in the immunopathogenesis of multiple sclerosis","volume":"160","author":"Gharibi","year":"2020","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00724_bib8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ana.27143","article-title":"Different treatment outcomes of multiple sclerosis patients receiving ocrelizumab or ofatumumab","volume":"97","author":"Meuth","year":"2025","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00724_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00724_bib10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1474-4422(22)00446-X","article-title":"Ublituximab: a new anti-CD20 agent for multiple sclerosis","volume":"21","author":"Oh","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00724_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00724_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00724_bib13","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","article-title":"The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurol Ther"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00724_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","article-title":"Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study","volume":"82","author":"Sorensen","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00724_bib15","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00724_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20(+) B-Cell-Depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00724_bib17","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.4049\/jimmunol.1600811","article-title":"Type I CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells","volume":"197","author":"Engelberts","year":"2016","journal-title":"J Immunol"},{"issue":"20","key":"10.1016\/j.neurot.2025.e00724_bib18","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00724_bib19","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II","volume":"28","author":"Gartner","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00724_bib20","first-page":"1","article-title":"Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice","author":"Amin","year":"2025","journal-title":"Neurodegener Dis Manag"},{"issue":"15-16","key":"10.1016\/j.neurot.2025.e00724_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10354-022-00939-w","article-title":"An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : immunotherapy with rituximab, ocrelizumab, and ofatumumab","volume":"172","author":"Ovchinnikov","year":"2022","journal-title":"Wien Med Wochenschr"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00724_bib22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00415-021-10676-6","article-title":"PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study","volume":"269","author":"Chisari","year":"2022","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00724_bib23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00724_bib24","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/ene.15406","article-title":"Confirmed disability progression as a marker of permanent disability in multiple sclerosis","volume":"29","author":"Sharmin","year":"2022","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00724_bib25","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/1352458517703193","article-title":"No evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Mult Scler"},{"issue":"11\u201312","key":"10.1016\/j.neurot.2025.e00724_bib26","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00724_bib27","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210049","article-title":"Ocrelizumab in early-stage relapsing-remitting multiple sclerosis: the phase IIIb ENSEMBLE 4-year, single-arm, open-label trial","volume":"103","author":"Hartung","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00724_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241239453","article-title":"Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons","volume":"17","author":"Riley","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00724_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-025-00784-0","article-title":"Five-year safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis","author":"Hauser","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2025.e00724_bib30","article-title":"Real-world data confirms effectiveness and safety of ofatumumab in MS","author":"Ferrazzano","year":"2025","journal-title":"European Academy of Neurology"},{"key":"10.1016\/j.neurot.2025.e00724_bib31","article-title":"Anti-CD20 therapies shown to be effective after switch from natalizumab M Meglio","author":"Meglio","year":"2023","journal-title":"ECTRIMS"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00724_bib32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/1352458514549401","article-title":"Significant clinical worsening after natalizumab withdrawal: predictive factors","volume":"21","author":"Vidal-Jordana","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00724_bib33","doi-asserted-by":"crossref","first-page":"101498","DOI":"10.1016\/j.msard.2019.101498","article-title":"Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation","volume":"38","author":"Mustonen","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00724_bib34","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1212\/CPJ.0000000000000809","article-title":"Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice","volume":"10","author":"Hersh","year":"2020","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.neurot.2025.e00724_bib35","doi-asserted-by":"crossref","first-page":"1500763","DOI":"10.3389\/fneur.2024.1500763","article-title":"Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study","volume":"15","author":"Fernandes","year":"2024","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00724_bib36","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1177\/13524585211044479","article-title":"Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study","volume":"28","author":"Bar-Or","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00724_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105605","article-title":"Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: a systematic review","volume":"86","author":"Brown","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00724_bib38","doi-asserted-by":"crossref","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de Seze","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00724_bib39","doi-asserted-by":"crossref","first-page":"1383910","DOI":"10.3389\/fneur.2024.1383910","article-title":"Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system","volume":"15","author":"Scavone","year":"2024","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00724_bib40","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1007\/s00415-024-12581-0","article-title":"Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study","volume":"271","author":"Karl","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00724_bib41","article-title":"Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurot.2025.e00724_bib42","doi-asserted-by":"crossref","first-page":"1515730","DOI":"10.3389\/fimmu.2025.1515730","article-title":"The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00724_bib43","doi-asserted-by":"crossref","first-page":"104881","DOI":"10.1016\/j.msard.2023.104881","article-title":"Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic","volume":"78","author":"Coyle","year":"2023","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:34:28Z","timestamp":1763638468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1878747925002028"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00724","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from na\u00efve and switch patients","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00724"}}